Overview

Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)

Status:
Recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib.
Phase:
Phase 1
Details
Lead Sponsor:
Mohammed Milhem
Treatments:
Palbociclib
Pembrolizumab